Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,461 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Solid Neoplasm Clear all
Terminated Phase 1Phase 2 Interventional Results available

Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma

NCT01610570
View directory record Official record
Conditions
Ewing Sarcoma, Sarcoma
Interventions
Mithramycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

NCT00054483
View directory record Official record
Conditions
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
bortezomib, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 22, 2026, 5:55 PM EDT
Not listed Phase 1Phase 2 Interventional

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

NCT00002482
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
antibody therapy, biological therapy, muromonab-CD3, cyclophosphamide
Biological · Drug
Lead sponsor
St. Vincent Medical Center - Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 22, 2026, 5:55 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
CRB-701, Anti-PD-1
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Active, not recruiting Not applicable Interventional

Virtual Art Therapy Assisted Re-Integration to Improve Biopsychosocial Outcomes in Adolescent and Young Adult Cancer Survivors, AVATARS Trial

NCT07089927
View directory record Official record
Conditions
Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Art Therapy, Interview, Survey Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
10 Years to 25 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors

NCT01670175
View directory record Official record
Conditions
Malignant Solid Tumor, Childhood Solid Tumor
Interventions
Sirolimus, Cyclophosphamide, Topotecan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 22, 2026, 5:55 PM EDT
Terminated Phase 1 Interventional

SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma

NCT00101244
View directory record Official record
Conditions
Adult Grade III Lymphomatoid Granulomatosis, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
ispinesib, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery

NCT02496065
View directory record Official record
Conditions
Tumors, Breast
Interventions
BLZ-100
Drug
Lead sponsor
Blaze Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Bellevue, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function

NCT00002901
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 22, 2026, 5:55 PM EDT
Recruiting No phase listed Observational

Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors

NCT00900471
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
biologic sample preservation procedure, medical chart review
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors

NCT00047242
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
7-hydroxystaurosporine, irinotecan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 22, 2026, 5:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT01109394
View directory record Official record
Conditions
Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Weeks and older
Enrollment
6,035 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Orange, Florida • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors

NCT01470365
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
quality-of-life assessment, intensity-modulated radiation therapy, 3-dimensional conformal radiation therapy
Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1Phase 2 Interventional

VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin

NCT00004030
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
VX-853, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1Phase 2 Interventional

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

NCT00387322
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
erlotinib hydrochloride, pemetrexed disodium
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

BMS-214662 in Treating Patients With Advanced Solid Tumors

NCT00004877
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BMS-214662
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2009 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Not applicable Interventional

Primary Care Physicians' Use of Stop-Smoking Plans to Help Patients Who Are Smokers

NCT00227786
View directory record Official record
Conditions
Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
smoking cessation intervention, counseling intervention
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
5
States / cities
Aurora, Colorado • Honolulu, Hawaii • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 22, 2026, 5:55 PM EDT
Terminated Phase 1 Interventional

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

NCT00060112
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oblimersen sodium, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Not applicable Interventional Results available

Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy

NCT00924651
View directory record Official record
Conditions
Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
exercise
Behavioral
Lead sponsor
Gary Morrow
Other
Eligibility
21 Years to 120 Years
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 22, 2026, 5:55 PM EDT
Terminated Phase 1 Interventional

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

NCT00733031
View directory record Official record
Conditions
Cancer,, Solid Tumors, Advanced Solid Malignancies
Interventions
AZD6918, gemcitabine, pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2010 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors

NCT00003768
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fosbretabulin disodium
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00039390
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, gefitinib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional Results available

Benzoylphenylurea in Treating Patients With Advanced Solid Tumors

NCT00016354
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
benzoylphenylurea
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Oct 22, 2026, 5:55 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Psychotherapy Intervention for Latinos With Adv Cancer

NCT04537936
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Adult, Solid Tumor, Unspecified, Adult
Interventions
Meaning Centered Psychotherapy for Latinos, Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale, Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients, Pre-assessment questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 5:55 PM EDT